Included in the six is a version of Bristol-Myers Squibb’s rheumatoid arthritis drug, Orencia (abatacept), the other five biosimilars have not yet been specified.

Momenta will receive an advance payment of US$45 million from Mylan and up to US$200 million in milestone payments. Both companies will be jointly responsible for product development and Mylan will lead on global commercialization. Costs and profits will be shared equally.

Mr Craig A Wheeler, Momenta’s President and Chief Executive Officer, said that the collaboration combined ‘Momenta’s proven capabilities in complex product development and Mylan’s world-class R & D supply chain and commercial infrastructure’.

The collaboration will also benefit from Mylan’s partnership with Biocon, its existing biologicals and insulin analogue partner, who is developing six biosimilar programmes and three insulin analogue programmes, five of which have completed phase I clinical trials, and four are in active phase II testing.

Related articles
Baxalta and Momenta start phase III trial for adalimumab biosimilar 

Roche updates position on biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.